BDTX Black Diamond Therapeutics
- 5.320
- -0.150-2.74%
- 5.330
- +0.010+0.19%
Black Diamond Therapeutics News
Black Diamond Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Black Diamond Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Black Diamond Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Black Diamond Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Behbahani Ali
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Kulkarni Samarth
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Menzel Garry E
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Raman Prakash
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Campbell Shannon
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Dhingra Kapil
Black Diamond Therapeutics | 8-K: Current report
Black Diamond Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Ali Behbahani(8.1%),New Enterprise Associates 16, L.P.(7.9%), etc.
Black Diamond Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RA Capital Management, L.P.(4.95%),Peter Kolchinsky(4.95%), etc.
Black Diamond Therapeutics | 10-Q: Quarterly report
Black Diamond Therapeutics | 8-K: Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Black Diamond Therapeutics | ARS: Annual Report to Security Holders
Black Diamond Therapeutics | DEFA14A: Others
Black Diamond Therapeutics | DEF 14A: Definitive information statements
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Campbell Shannon
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Raman Prakash
Analysis
Price Target
No Data
